Pharma and healthcare companies to face continued margin pressure: HDFC Securities

The Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the March quarter, according to a brokerage report by HDFC Securities. "We project sales/EBITDA growth of 11%/6% YoY for our coverage universe," the brokerage added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ys0ISVq
via IFTTT